Octreotide Acetate

Acromegaly, Flushing, Gastroenteritis + 4 more

Treatment

6 FDA approvals

17 Active Studies for Octreotide Acetate

What is Octreotide Acetate

Octreotide

The Generic name of this drug

Treatment Summary

Acromegaly is a disorder caused by too much growth hormone in the body, changing the size of body tissues and resulting in metabolic issues. It is usually caused by a tumor in the pituitary gland. Symptoms may include abnormally large feet, hands and face, as well as organ enlargement and insulin resistance. Octreotide is a medication that mimics the natural hormone somatostatin, which helps to prevent the secretion of growth hormone. It is used to treat acromegaly and other tumors, such as carcinoid tumors and VIPomas. On June 26, 2020, Mycapssa, the first FDA

Octreotide Acetate

is the brand name

image of different drug pills on a surface

Octreotide Acetate Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Octreotide Acetate

Octreotide

1988

89

Approved as Treatment by the FDA

Octreotide, otherwise known as Octreotide Acetate, is approved by the FDA for 6 uses such as metastatic Carcinoid Tumors and Gastroenteritis .

metastatic Carcinoid Tumors

Gastroenteritis

Diarrhea

Carcinoid Tumor

Acromegaly

Helps manage Acromegaly

Flushing

Effectiveness

How Octreotide Acetate Affects Patients

Octreotide is a hormone-like medication that works similarly to the natural hormone somatostatin. It can help treat abnormal tissue growth and poor insulin regulation in people with acromegaly, and can also reduce flushing and diarrhea in those with gastrointestinal tumors. Taking octreotide may reduce the function of the gallbladder and bile secretion, as well as reduce levels of thyroid-stimulating hormone (TSH) and vitamin B12. People using this medication should have their vitamin B12 levels monitored.

How Octreotide Acetate works in the body

Octreotide targets the hormones that cause abnormal growth, like growth hormone, luteinizing hormone, and serotonin. It works by blocking the receptors that receive these hormones and causes them to become inactive. Octreotide also reduces blood flow to the digestive organs, which can help relieve gastrointestinal symptoms. This drug can be used to treat acromegaly and carcinoid and/or VIPoma tumors.

When to interrupt dosage

The proposed dosage of Octreotide Acetate is contingent upon the detected malady, including Acromegaly, Vasoactive Intestinal Peptide Tumors and metastatic Carcinoid Tumors. The amount of dosage can be located in the table below, based on the delivery approach (e.g. Injection - Intravenous; Subcutaneous or Capsule, delayed release).

Condition

Dosage

Administration

Flushing

, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL

Injection, solution, Intravenous; Subcutaneous, Injection, solution - Intravenous; Subcutaneous, , Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Kit - Intramuscular

Carcinoid Tumor

, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL

Injection, solution, Intravenous; Subcutaneous, Injection, solution - Intravenous; Subcutaneous, , Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Kit - Intramuscular

octreotide

, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL

Injection, solution, Intravenous; Subcutaneous, Injection, solution - Intravenous; Subcutaneous, , Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Kit - Intramuscular

Acromegaly

, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL

Injection, solution, Intravenous; Subcutaneous, Injection, solution - Intravenous; Subcutaneous, , Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Kit - Intramuscular

Gastroenteritis

, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL

Injection, solution, Intravenous; Subcutaneous, Injection, solution - Intravenous; Subcutaneous, , Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Kit - Intramuscular

Vasoactive Intestinal Peptide Tumors

, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL

Injection, solution, Intravenous; Subcutaneous, Injection, solution - Intravenous; Subcutaneous, , Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Kit - Intramuscular

long-term maintenance therapy

, 1.0 mg/mL, 0.2 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 10.0 mg, 20.0 mg, 30.0 mg, 3.33 mg/mL, 5.0 mg/mL, 1.667 mg/mL, 2.5 mg/mL

Injection, solution, Intravenous; Subcutaneous, Injection, solution - Intravenous; Subcutaneous, , Injection, Injection - Intravenous; Subcutaneous, Solution, Solution - Intravenous; Subcutaneous, Intramuscular, Kit, Injection - Intravenous, Intravenous, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection - Subcutaneous, Subcutaneous, Capsule, delayed release, Oral, Capsule, delayed release - Oral, Injection, powder, for suspension, extended release; Kit - Intramuscular, Injection, powder, for suspension, extended release; Kit, Kit - Intramuscular

Warnings

Octreotide Acetate Contraindications

Condition

Risk Level

Notes

known hypersensitivity to the drug or any of the ingredients

Do Not Combine

There are 20 known major drug interactions with Octreotide Acetate.

Common Octreotide Acetate Drug Interactions

Drug Name

Risk Level

Description

Dotatate gallium Ga-68

Major

Octreotide may decrease effectiveness of Dotatate gallium Ga-68 as a diagnostic agent.

Eliglustat

Major

The metabolism of Eliglustat can be decreased when combined with Octreotide.

Fentanyl

Major

The metabolism of Fentanyl can be decreased when combined with Octreotide.

Hydroxyzine

Major

The risk or severity of QTc prolongation can be increased when Octreotide is combined with Hydroxyzine.

Lutetium Lu 177 dotatate

Major

The therapeutic efficacy of Lutetium Lu 177 dotatate can be decreased when used in combination with Octreotide.

Octreotide Acetate Toxicity & Overdose Risk

Octreotide overdose can lead to a variety of side effects, including low blood pressure, reduced oxygen to the brain, irregular heartbeat, heart attack, excess lactic acid in the body, inflammation of the pancreas, enlargement of the liver, diarrhea, reddening of the skin, tiredness, and weakness.

image of a doctor in a lab doing drug, clinical research

Octreotide Acetate Novel Uses: Which Conditions Have a Clinical Trial Featuring Octreotide Acetate?

41 active clinical trials are being conducted to assess the potential of Octreotide Acetate in providing therapeutic benefit for metastatic Carcinoid Tumors, Flushing and long-term maintenance therapy.

Condition

Clinical Trials

Trial Phases

Acromegaly

6 Actively Recruiting

Phase 2, Phase 3, Phase 1

Flushing

0 Actively Recruiting

Gastroenteritis

12 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Early Phase 1

Vasoactive Intestinal Peptide Tumors

0 Actively Recruiting

Carcinoid Tumor

1 Actively Recruiting

Early Phase 1

long-term maintenance therapy

0 Actively Recruiting

octreotide

0 Actively Recruiting

Octreotide Acetate Reviews: What are patients saying about Octreotide Acetate?

5

Patient Review

3/12/2012

Octreotide Acetate for Carcinoid Syndrome

I take one large shot at the hospital every 21 days and 1-3 shots daily at home. Before, I couldn't sleep due to side effects like sweating, flushing, stomach upset, and needing to be near a restroom for 4-6 hours after eating. Now I'm back to working full time, maintaining my weight, and enjoying life outside the house. Thank god for health insurance--I don't know how people manage without it if they have to rely on government assistance.

4.7

Patient Review

12/28/2010

Octreotide Acetate for Carcinoid Syndrome

Octreotide was a lifesaver for me. I had severe nausea and diarrhea after surgery, to the point where I lost 20 pounds. This medication completely cured those symptoms and allowed me to regain my strength and weight.

4.3

Patient Review

3/22/2011

Octreotide Acetate for Syndrome After Rapid Passage of Food Into Small Intestine

I've been using this treatment for 17 years, and it's helped me a lot. Recently I've started having some difficulty getting the same results, but overall it's still a great medication.

4.3

Patient Review

7/31/2011

Octreotide Acetate for An Abnormal Connection Between the Stomach and Intestine

I've just started this medication and I'm not sure of the effects yet.

4

Patient Review

1/15/2011

Octreotide Acetate for Carcinoid Syndrome

I receive monthly injections for carcinoid cancer of the small intestine which has metastisized to the liver. My diahrea, flushing, pain has decreases somewhat. I still have diahrea afer each meal but it is not as watery. Certain foods trigger my attacks, so I have to be real careful while eating. I am weak and sometimes confused, could be the drug.

1

Patient Review

4/28/2012

Octreotide Acetate for Chylothorax

I started with 100 micrograms twice a day, self injected in my abdomen. I had severe diarrhea right from the start. The dosage was reduced to 100micrograms once a day, with same result. the dosage was reduced to 50 micrograms once a day and the diarrhea continued.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about octreotide acetate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Why is octreotide used in GI bleed?

"Octreotide can also be given as a continuous infusion.

Octreotide inhibits the secretion of acid and pepsin, preventing the dissolution of freshly formed clots. It can also be given as a continuous infusion."

Answered by AI

Is octreotide a chemo drug?

"(2018). Chemocare.com. Retrieved from https://chemocare.com/chemotherapy/drug-info/octreotide.aspx

Octreotide is used to treat certain types of cancer. It is a man-made protein that is similar to a hormone found in the body. Octreotide works by slowing the growth of certain tumors and by decreasing the amount of certain hormones in the body. Octreotide is used to treat the following types of cancer: acromegaly, carcinoid tumors, neuroendocrine tumors, and VIPomas."

Answered by AI

What is octreotide acetate used for?

"Octreotide is used to stop severe watery diarrhea and sudden reddening of the face and neck caused by certain types of tumors. These tumors are usually found in the intestines and pancreas."

Answered by AI

What is the action of octreotide?

"The drug octreotide mimics the effects of the hormone somatostatin. Somatostatin regulates growth hormone and insulin, so octreotide is effective in treating disorders like acromegaly that involve abnormal tissue growth and insulin regulation."

Answered by AI

Clinical Trials for Octreotide Acetate

Image of Stanford Digestive Health Clinic in Redwood City, United States.

MITI-001 for Irritable Bowel Syndrome

18 - 65
All Sexes
Redwood City, CA

While the pathophysiology of diarrhea-predominant irritable bowel syndrome (IBS-D) is complex and heterogeneous, dysbiosis of the gut microbiome is frequently observed, suggesting that a substantial subset of patients with irritable bowel syndrome (IBS) have symptoms that are initiated and/or perpetuated by a microbiome dysfunction. Successful randomized controlled trials (RCT) for IBS-D (Ford 2018; Black 2022) leveraging microbiome-targeted therapies (antibiotics or low microbiome fermentation diets) suggest the gut microbiome is at least partially involved in IBS symptoms. Furthermore, fecal microbiota transplantation (FMT) for patients with IBS-D has demonstrated promising results (El-Salhy 2020), supporting the possibility that altering the microbiome composition could ameliorate IBS-D symptoms. MITI-001 is a transplantable gut bacterial community composed of 157 live bacterial strains, encompassing 79 genera of commensal bacteria, that have been isolated from healthy donor stool, purified, and banked. The hypothesis of the proposed research is that MITI-001 can target the pathophysiologic lesion in a subset of IBS-D patients, restore the altered microbial metabolic process, and thus alleviate IBS-D symptoms.

Phase < 1
Waitlist Available

Stanford Digestive Health Clinic (+1 Sites)

Sean P Spencer, MD, PhD

Have you considered Octreotide Acetate clinical trials?

We made a collection of clinical trials featuring Octreotide Acetate, we think they might fit your search criteria.
Go to Trials

Have you considered Octreotide Acetate clinical trials?

We made a collection of clinical trials featuring Octreotide Acetate, we think they might fit your search criteria.
Go to Trials

Have you considered Octreotide Acetate clinical trials?

We made a collection of clinical trials featuring Octreotide Acetate, we think they might fit your search criteria.
Go to Trials